GURUFOCUS.COM » STOCK LIST » UK/Ireland » UK » NEXX » Scancell Holdings PLC (NEXX:SCLP.GB) » Definitions » 5-Year ROIIC %
Switch to:

Scancell Holdings (NEXX:SCLP.GB) 5-Year ROIIC %

: -73.15% (As of Apr. 2022)
View and export this data going back to 2013. Start your Free Trial

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Scancell Holdings's 5-Year ROIIC % for the quarter that ended in Apr. 2022 was -73.15%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Scancell Holdings's 5-Year ROIIC % or its related term are showing as below:

NEXX:SCLP.GB's 5-Year ROIIC % is ranked worse than
59.44% of 1452 companies
in the Biotechnology industry
Industry Median: -32.05 vs NEXX:SCLP.GB: -73.15

Competitive Comparison

For the Biotechnology subindustry, Scancell Holdings's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings 5-Year ROIIC % Distribution

For the Biotechnology industry and Healthcare sector, Scancell Holdings's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's 5-Year ROIIC % falls in comparison to its industry or sector. The grey bar indicates the 5-Year ROIIC %'s extreme value range as defined by GuruFocus.

Scancell Holdings 5-Year ROIIC % Calculation

Scancell Holdings's 5-Year ROIIC % for the quarter that ended in Apr. 2022 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -7.287852 (Apr. 2022) - -3.5877963 (Apr. 2017) )/( 8.885 (Apr. 2022) - 3.827 (Apr. 2017) )
=-73.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

**Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.

Scancell Holdings  (NEXX:SCLP.GB) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Scancell Holdings 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's 5-Year ROIIC % provided by Please click on the following links to see related term pages.

Scancell Holdings (NEXX:SCLP.GB) Business Description

Scancell Holdings logo
Traded in Other Exchanges
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (NEXX:SCLP.GB) Headlines

No Headlines